Less than 10% of individuals who could benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial guidance on the therapies.
Considering over a billion individuals worldwide now classified as obese, it is calling for more widespread and fairer access to GLP-1 medication.
Per projections, more than two billion will be obese by 2030 without intervention.
"Our new guidance recognises that excess weight is a chronic disease that can be addressed with comprehensive and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major obstacles to broad availability to the jabs that can aid individuals in losing significant weight, says the organization.
GLP-1 Therapy Scarcity
Even under the present most favorable case, the production of GLP-1 therapies could only cover approximately 100 million people – less than 10% of the global need, as stated by the health organization.
The guideline calls on countries and companies to widen availability, by strategies like licensing agreements.
A patent on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Injections Operate
These medications imitate a body's own hormone to slow digestion, curb appetite and boost the sense of being full so individuals reduce food intake.
People typically begin shedding pounds in the initial weeks of beginning the weekly injections.
Research indicates patients may regain a significant portion within a year of stopping the treatment, when their normal hunger come back.
Being overweight or obese elevates your chance for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity impacts individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
